

Resource Summary Report

Generated by PRECISE-TBI on Sep 1, 2026

Brilliant Violet 421(TM) anti-mouse/human KLRG1 (MAFA)

RRID:AB_2565613

Type: Antibody

Proper Citation

BioLegend Cat# 138414, RRID:AB_2565613

Antibody Information

URL: http://antibodyregistry.org/AB_2565613

Proper Citation: BioLegend Cat# 138414, RRID:AB_2565613

Target Antigen: KLRG1

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-mouse/human KLRG1 (MAFA)

Description: This monoclonal targets KLRG1

Target Organism: mouse, human

Clone ID: Clone 2F1/KLRG1

Antibody ID: AB_2565613

Vendor: BioLegend

Catalog Number: 138414

Alternative Catalog Numbers: 138413

Record Creation Time: 20250820T060201+0000

Record Last Update: 20250820T230720+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse/human KLRG1 (MAFA).

No alerts have been found for Brilliant Violet 421(TM) anti-mouse/human KLRG1 (MAFA).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Atakkatan A, et al. (2025) Complement-producing adventitial fibroblasts form an IL-33 alarmin hub that maintains ILC2s during airway allergy. *Cell reports*, 44(12), 116641.

Wang Y, et al. (2025) Bi-directional communication between intrinsic enteric neurons and ILC2s inhibits host defense against helminth infection. *Immunity*, 58(2), 465.

Bündgen G, et al. (2025) Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells. *Immunity*, 58(8), 2019.

Lin CP, et al. (2024) Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness. *Cancer cell*.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. *Immunity*, 56(1), 207.

Eschweiler S, et al. (2023) JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells. *Cell reports*, 42(2), 112040.

Huang Q, et al. (2022) The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. *Cell*, 185(22), 4049.

Delacher M, et al. (2021) Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. *Immunity*, 54(4), 702.

Herndler-Brandstetter D, et al. (2018) KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. *Immunity*, 48(4), 716.

Wang D, et al. (2018) The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation. *Immunity*, 48(4), 659.